Cardio Diagnostics (NASDAQ:CDIO) PT Lowered to $1.35 at Benchmark

Cardio Diagnostics (NASDAQ:CDIO) had its target price decreased by equities researchers at Benchmark from $4.00 to $1.35 in a report issued on Friday, Benzinga reports. The firm currently has a “speculative buy” rating on the stock. Benchmark’s target price suggests a potential upside of 23.85% from the company’s current price.

Cardio Diagnostics Trading Up 6.9 %

CDIO stock opened at $1.09 on Friday. The business’s fifty day simple moving average is $1.43 and its two-hundred day simple moving average is $1.51. Cardio Diagnostics has a twelve month low of $0.17 and a twelve month high of $3.56.

Hedge Funds Weigh In On Cardio Diagnostics

A number of hedge funds and other institutional investors have recently made changes to their positions in CDIO. Bank of America Corp DE bought a new position in shares of Cardio Diagnostics during the 1st quarter worth $59,000. Geode Capital Management LLC bought a new stake in Cardio Diagnostics during the first quarter valued at about $290,000. State Street Corp bought a new stake in Cardio Diagnostics during the first quarter valued at about $163,000. Vontobel Holding Ltd. bought a new stake in Cardio Diagnostics during the fourth quarter valued at about $30,000. Finally, Northern Trust Corp bought a new stake in Cardio Diagnostics during the fourth quarter valued at about $115,000. Institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.